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ABSTRACT 
Objective. In patients with lung cancer, whole-body 2-deoxy-2- C8F]fluoro-D-
glucose with positron-emission tomography (FDG-PET) scan and bone 
scintigraphy are common staging studies, both with the ability to detect osseous 
metastasis. There is some evidence that PET scan is superior to bone scan and 
that bone scan can be replaced by PET scan. The purpose of this study was to 
compare the test characteristics and agreement ofFDG-PET to bone scintigraphy 
for the detection of bony metastases in the staging of patients with newly 
diagnosed lung cancer. 
Subjects and Methods. We queried the tumor registry and nuclear medicine 
database at Duke University Medical Center to identify all patients between July 
1998 and August 2002 with a new diagnosis of lung cancer, FDG-PET scan, and a 
bone scan prior to therapy. We retrospectively reviewed these patients' radiologic 
reports and entered them into a database. We used specific clinical criteria to 
confirm bone metastases, integrating all available clinical information. We then 
calculated the sensitivity, specificity, and likelihood ratios for each study. 
Results. Two hundred and fifty-seven patients fulfilled the entrance criteria. One 
hundred and four patients ( 40%) presented with stage IV disease, and we 
confirmed bone metastases in 57 (22%) patients. We calculated the sensitivity 
values of PET and bone scan as 91% and 63-75%, and specificity values as 96% 
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-
and 92-95%, respectively. Likelihood ratios of positive PET and bone scans were 
greater than 20. Likelihood ratios of negative PET and bone scans were 0.08 and 
0.16, respectively. The likelihood ratio of equivocal bone scans was 3.5. The 
weighted-kappa statistic suggested moderate agreement between the two 
modalities (Kw = 0.510, 95% CI, 0.402- 0.618). 
Elimination of bone scan in this cohort would have resulted in 7 (3%) of257 
patients with false positive PET results for bone metastasis, but in no case would 
patient management have been adversely affected. Similarly, 5 (1 %) of257 
patients with bone metastases had false negative PET results, but in all cases there 
was other radiographic evidence of extrathoracic metastasis and Stage N disease 
by CT scan or PET. 
Conclusions. The use ofboth whole-body PET and bone scintigraphy as initial 
staging studies in lung cancer patients may provide redundant information about 
the presence of bony metastases. The improvement in accuracy and sensitivity 
with PET suggests bone scan could potentially be eliminated from the staging 
evaluation at presentation, but these results are limited by sub-optimal study 
design. We recommend a prospective trial with appropriate verification of bony 








Background. Lung cancer is the leading cause of cancer death in the 
world.1 In the United States alone, lung cancer will cause an estimated 157,000 
deaths this year, equal to the number of deaths from prostate, breast, and colon 
cancer combined? 
Of the roughly 153,000 Americans who die each year from lung cancer, 
smoking accounts for 125,000 (82%) deaths? Smoking cessation has long been 
known the most effective form of lung cancer prevention. There is a dose-
response relationship between the amount of tobacco exposure and the 
development oflung cancer.1 Increased public awareness of the numerous health 
risks of smoking including lung cancer resulted in an overall40% decline in 
smoking prevalence in the United States between 1965 and 1990. Since then, 
smoking prevalence has remained constant. Currently, 25.7% of adult US males 
(24.3 million) and 21.5% of adult US females (22.2 million) are smokers. The 
percentage of high school children who report current cigarette smoking is even 
higher at 28.5%. Projections of current smoking patterns suggest lung cancer will 
remain the world's leading cause of cancer death for at least the next several 
decades to come.4 
Staging of Lung Cancer. Among patients who develop lung cancer, 
accurate staging is essential for patient management and in determining the 
optimal therapeutic strategy.5·7 Identification of patients with distant metastasis 
(Stage N disease) precludes curative surgery. Patients staged with localized 
Stage I or II disease have greater than 50% 5-year survival, but this figure drops 
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sharply to 20% in patients with Stage III disease and less than 2% 5-year survival 
in patients with Stage N lung cancer.8-10 The aforementioned statistics are 
subject to lead-time bias and thus unreliable for determining lung cancer 
screening policy. However, the data show clearly that Stage N lung cancer 
patients have a dismal prognosis and confirm the current view that Stage N 
patients cannot be cured by surgical resection. Unfortunately, only 15% oflung 
cancer patients present with localized Stage I or Stage II disease. 5 
Inability to detect Stage N disease in lung cancer patients on presentation 
results in higher cost and increased morbidity associated with futile surgical 
intervention. Therefore, diagnostic workup of lung cancer patients always starts 
with a search for distant metastasis. 11 • 12 A series of radiographic tests performed 
upon initial diagnosis oflung cancer is used to identifY patients with Stage N 
disease. Clinical staging at the time of presentation is typically performed using a 
series oftargeted diagnostic imaging studies including computed-tomography 
(CT) of the thorax through the liver and adrenal glands, CT and/or magnetic 
resonance (MR) imaging of the head, and radionuclide bone scintigraphy (bone 
scan). In the case of solitary lesions of unknown origin in liver, adrenal gland, or 
bone, biopsy is occasionally used to remove diagnostic uncertainty. 
An important consideration is that 40% of patients undergoing "curative" 
resection have a recurrence oflung cancer. 8 This fact suggests current methods of 
staging are frequently missing the presence of distant metastasis. Thus, 
researchers have been searching for new modalities to more accurately stage lung 
cancer patients and detect regional and distant spread. 
4 
FDG-PET in Lung Cancer. More recently, researchers have suggested 
whole-body 2-deoxy-2- [ 18F]fluoro-D-glucose (FDG) with positron-emission 
tomography (PET) as an alternative study, which could provide a more accurate 
and efficient diagnostic approach than the combination of conventional imaging 
studies. 13-17 FDG-PET is a type of functional imaging based on the principle that 
malignant tumors have a higher metabolic rate than benign tumors or background 
physiologic activity. Malignant cells thus preferentially accumulate higher 
concentrations ofFDG than surrounding tissue. FDG is irreversibly trapped in 
cells and unable to undergo further metabolism after the first phosphorylation step 
of glycolysis, which allows for the detection of areas of high metabolic activity 
corresponding to malignancy or infection.18 False-positive PET results occur in 
areas of increased metabolism such as infection. Another potential drawback of 
PET scanning is the inability to localize areas of hypermetabolism with anatomic 
precJsJOn. 
PET scanning has become an accepted tool for diagnostic evaluation and 
initial staging oflung cancer as evidenced by approval of Medicare coverage 
since January 1998Y· 19 Medicare expanded coverage to the diagnosis, staging, 
restaging of non-small cell lung cancer in July 2001.19 
A recent meta-analysis of good quality examined the overall accuracy of 
PET for regional lymph node staging in lung cancer, showing it to be superior to 
that of conventional staging with CT .zo While none ofthe 29 included studies 
fulfilled all of the authors' prospectively-defined criteria for study quality, all 
studies used an objective gold standard for evaluation oflymph nodes. The gold 
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standard was pathologic evaluation of lymph nodes from either mediastinoscopy, 
thoracotomy, or autopsy. Seventy percent ofthe studies in the meta-analysis were 
prospective. 
Another meta-analysis of lesser quality analyzed PET accuracy in the 
evaluation of malignancy in indeterminate puhnonary nodules. This meta-
analysis placed the sensitivity and specificity of PET at 97% and 78%, 
respectively.21 Many of the studies had incomplete blinding, and the authors 
assessed the included studies as being of fair quality overall. The authors defined 
minimum eligibility criteria for inclusion in the meta-analysis and later performed 
an assessment of quality of the included studies. In other words, study quality 
was not part of the inclusion criteria. As a result, 5 of3 7 FDG-PET studies 
included in the meta-analysis did not even meet the authors' quality criteria for 
having an appropriate reference standard. 
FDG-PET in Extrathoracic Staging of Lung Cancer. There is 
controversy in the medical literature about the ideal imaging approach to search 
for extra-thoracic metastases in bone and other distant sites. At Duke University 
Medical Center, the pattern of diagnostic imaging in patients with lung cancer 
differs depending on the type of clinic. All patients presenting to thoracic 
surgeons at DUMC for diagnostic workup and possible curative surgical resection 
oflung cancer undergo thoracic CT scan and whole-body PET scan. Thoracic 
surgeons at Duke do not search for lung cancer metastasis to bone or brain unless 
patients demonstrate clinical symptoms such as bone pain or focal neurological 
symptoms. s, 6• 14 However, at the Duke thoracic oncology clinic, all patients 
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determined to be Stage IIIB, Stage IV, or medically-inoperable invariably 
undergo bone scan and imaging of the head. 11 ' 14 The frequency and pattern of 
utilization of PET in the Duke thoracic oncology clinic depends on the pattern of 
use of previous imaging modalities and corresponding results. While patients in 
the oncology clinic often have metastatic disease that rules them out from curative 
surgery, identification of bone metastases can provide important information 
about baseline level of disease and response to therapy. 
Several studies including 2 prospective cohort studies and I randomized, 
controlled trial have shown PET to be beneficial for extra-thoracic staging in the 
overall search for metastatic disease in lung cancer.14' 17' 21 ' 23 In II% of patients, 
PET can identify clinically silent metastasis missed by other conventional 
imaging modalities?3 The results of PET change patient management in greater 
than 26% of lung cancer patients by upstaging them to palliative therapy from 
curative surgery.22-24 
Bone metastases. Bone is a common site of metastasis in patients with 
lung cancer, but its diagnosis can be difficult. 14 The pathophysiology of bone 
metastasis is thought to begin with seeding of bone by micrometastases after 
spread of malignant tumor cells into the bloodstream. 25 Micrometastatic spread to 
bone can be detected by immunohistochemical stains of bone marrow aspirates?6 
However, the simple presence of micrometastatic lung cancer in bone is not 
necessarily diagnostic of clinically important metastasis to bone, nor is it a good 
indicator of patient outcome.27 Many clinicians exclude the diagnosis of bone 







negative predictive value of absent bone pain is greater than 90% according to 
some studies. 14 This approach is fraught with uncertainty, since some series 
report 40% of lung cancer patients with proven bone metastasis as 
. 28 
asymptomatic. 
Bone Scintigraphy in Lung Cancer. To date, the most common imaging 
study used to detect gross metastatic lesions of bone is bone scan with 
technetium-99m labeled methylene diphosphate. Other second-line imaging tests 
are MR imaging of bone and plain film radiography. Unlike FDG-PET, which 
detects increased glucose metabolism, bone scan is an indicator ofbone turnover 
through incorporation of radio labelled phosphate into bone. Bone scan is an 
imperfect imaging modality for detection of bone metastasis in lung cancer. It 
works best at detecting sclerotic metastases, because they contain areas of 
increased bone turnover and bone deposition. But lung cancer sometimes results 
in lytic metastases, resulting in a decreased sensitivity of bone scan.Z9 Sensitivity 
of bone scan is quite high according to previous studies, but the specificity is low 
with frequent false positives. 25• 28 This is largely due to radio tracer uptake in a 
multiplicity of benign conditions such as arthritic joints, previous skeletal trauma, 
Paget's disease, or benign inflammatory processes in a pattern indistinguishable 
from metastasis. 
Bone Scan and FDG-PET in Detection of Lung Cancer Bone 
Metastases. Given the ability of PET to detect osseous metastasis, several small 
series have indicated that the high accuracy of PET may obviate the need for a 
bone scan.17• 28• 30-32 Only four published studies have examined closely the 
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relative accuracy of PET scan and bone scan in the detection of bone metastases 
in lung cancer patients. 17• 28• 30• 31 We identified 3 studies through a search of the 
Medline and CINAHL databases with the search terms "bone scan", "bone 
scintigraphy", and "positron emission tomography" and the MeSH term "Lung 
Neoplasm". 17• 28•30 We obtained one study through consultation with an expert in 
the field.31 
No study made routine use of a gold standard such as bone biopsy. All 
studies employed a reference standard of follow-up bone scans over a period of 
several months, with occasional use of other radiographic imaging or bone biopsy 
when deemed appropriate by the treating physician. The Marom et.al. study had 
the most variable follow-up, ranging from 1 to 8 months, whereas all other studies 
had a minimum clinical follow-up period of9 months. 
Sensitivity and specificity values ranged from 90-93% and 98-99%, 
respectively. Sensitivity and specificity values of bone scan were much more 
variable, ranging from 50-94% and 61-92%, respectively. The wide range is due 
in part to study design. Study populations ranged from 48 to 110 patients but 
included no more than 21 patients determined in the final analysis to have osseous 
metastasis. The small number of patients with bone metastases resulted in wide 
confidence intervals of all results. 
All studies utilized blinded interpretation of radiographs by at least 2 
experienced reviewers. Ofthe four cohort studies, Marom et. al. was the only 
prospective one. No study accounted for the effect of chemotherapy on the 
potential interval resolution of metastatic bone lesions. 
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Bury et.al. viewed any abnormal uptake on bone scan as representative 
metastatic disease unless there was clear evidence of degenerative disease by 
prior radiographs or high clinical suspicion of the treating physician. This 
stringent criterion maximized the sensitivity of bone scan but handicapped its 
specificity. It is also not representative of bone scan interpretation by nuclear 
medicine physicians at DUMC or most other institutions. 
Hsia et.al. compared PET and bone scan on a lesion-by-lesion basis, 
L 
whereas the other studies performed a patient-by-patient analysis. Thus, it was 
= 
impossible to determine the effect on individual patients of excluding bone scan r 
or PET scan. 
Despite the consistency of results, all four studies had shortcomings in 
design. No study had a solid reference standard, and all studies had a very small 
number of patients affected by bone metastasis. 
Equivocal or Indeterminate Results. Since bone scan is well-known to 
demonstrate lesions of variable uptake which cannot differentiate between 
metastatic and degenerative disease, these lesions cannot be described as clearly 
positive or negative. Thus, results of bone scan are not dichotomous. Similarly, 
there can be difficulty differentiating on PET between location oftumor in 
peripheral lung or adjacent rib.31 However, the aforementioned studies have 
reported all PET and bone scan results as either positive or negative for bone 
metastasis, ignoring the clinical reality of equivocal or indeterminate results. This 
methodology of artificially forcing indeterminate diagnostic results into firm 
diagnostic categories of positive or negative raises questions about the validity 
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and clinical relevance of subsequent analysis and conclusions. 33• 34 Resultant 
calculations of sensitivity, specificity, and other diagnostic test characteristics can 
be misleading or inaccurate, with unintended financial or diagnostic implications. 
There is no consensus in the epidemiology literature of how to analyze 
indeterminate or equivocal results of diagnostic tests. 33 At the very least, 
investigators should report the existence of this diagnostic category and clearly 
specify their chosen method of addressing the category in the analysis. In 
general, indeterminate or equivocal results should not be excluded from the 
-
analysis, nor should they be placed in the standard 2x2 matrix. Researchers ~ t--
should consider developing likelihood ratios for the intermediate results. 
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Future ofFDG-PET in Lung Cancer. At DUMC, the cost of bone scan I 
F is approximately $400-$500, whereas PET scan is approximately $2200-2500. 
Although PET studies are clearly more expensive than bone scan and CT scan, 
utilization of PET is spreading beyond the realm of the tertiary-care, academic 
medical center. As the body of evidence supporting PET utilization in staging L i---
and diagnosis oflung cancer and other less-common cancers grows, availability 
of PET will increase rapidly in community medical practices. 
A recent prospective cohort study of 50 patients showed a statistically 
significant improvement in diagnostic accuracy with fusion of PET and CT 
images by combining the benefits of PET's functional imaging capabilities with 
the anatomic specificity of CT scan. 35 The gold standard was histopathological 
assessment of tumor stage and regional lymph nodes, and histopathological or 





physicians who treat lung cancer now view PET -CT fusion as a new standard of 
care for lung cancer staging and re-staging, and the current trend in radiology is 
toward the purchase of combination PET -CT fusion cameras. Since PET -CT 
fusion provides superior results compared to either modality alone, it is highly 
likely that a fused PET scan will accompany all future thoracic CT scans in lung 
cancer patients. The push for rapid acceptance and adoption of this new 
technology is understandable given the high prevalence of lung cancer and its 
dismal prognosis. However, immediately shifting the bulk of staging radiography 
to PET -CT fusion scans seems rash, given the paucity of supporting evidence and 
the high equipment cost. 
One current issue in extrathoracic staging oflung cancer is whether bone 
scan can provide clinical information over and above that supplied by PET. 
Evaluation of this question must begin with a comparison of the diagnostic test 
characteristics of both studies. The purpose of this study was to compare the 
agreement and test characteristics of PET scan to bone scan for the detection of 
distant bone metastases in patients with newly diagnosed lung cancer to determine 
if these were complementary or redundant studies. Based on the work of previous 
authors, we expect FDG-PET to have a statistically significant increase in 
sensitivity and specificity over bone scan. 
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SUBJECTS AND METHODS 
Study Design 
Several authors have described criteria to evaluate the quality of studies of 
diagnostic tests.36• 37 Two of the most important are blinding and use of a gold 
standard. In the design of diagnostic imaging tests, blinding of test interpreters is 
important because of the inherent subjectivity of evaluating the images. Outside 
clinical information is highly likely to influence the interpretations ofunblinded 
radiologists. Because of the retrospective design, we could not blind the 
radiologists interpreting the bone or PET scans in this study. Due to the large 
number of scans, we were able to recruit only one blinded radiologist to provide 
blinded interpretations, but these were only for scans with ambiguous or 
equivocal reports. Ideally, two blinded radiologists would provide independent 
interpretations of all scans with disputes resolved by a third observer or 
consensus. Their interobserver agreement would be calculated in the form of a K 
statistic. 
The gold standard for bone metastasis is a positive bone biopsy in a region 
ofbone pain or positive radiographic findings. This study employed an alternate 
but imperfect reference standard. The reference standard in this study and 
previous studies incorporated the results of PET scan and bone scan to determine 
the presence of bone metastasis. A long follow-up period aids in the assessment 
of bone lesions, because of the hypothesis that a metastatic lesion will change or 
increase in size over time, whereas a benign lesion will not. Follow-up periods in 
this study varied from no follow-up to 3 years. 
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The PET and bone studies should ideally be performed on the same day, 
or at least within several days of one another. The patient population selected for 
the study should reflect that seen in the general population where the two imaging 
tests would be utilized. A prospective study is preferable, because it can be 
designed to avoid many of the problems inherent in retrospective studies such as 
blinding and an objective and robust reference standard. 
Patient Selection 
We obtained approval of the institutional review board prior to the start of 
the study. The tumor registry and PET database at Duke University Medical 
. 
[ 
Center (DUM C) were retrospectively reviewed to identifY all patients with a I 
pathologically proved new diagnosis oflung cancer, and staging with both whole- ~ 
body PET and bone scan prior to the initiation of therapy. The review included 
1,100 patients with lung cancer diagnosed between July 1998 and December 
2000, and 2,000 consecutive patients who had a whole-body PET scan between 
September 2000 and August 2002. We chose these 2 data sets due to their ready 
availability. Though providing different starting points, both data sets should 
result in identification of all patients at DUMC who fulfill inclusion criteria for 
the specified time period. 
This search identified 257 patients, 106 women and 151 men (age range 
38-89 years; average age, 64.1 years) who fulfilled the entrance criteria and had 
sufficient followup to be considered eligible for analysis. 
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Interpretation oflmaging Studies 
One hundred and twenty-eight patients received bone scan before PET 
scan, with an average delay of 11.2 days (range 0- 133 days) between the scans. 
No patient had any therapeutic intervention between studies. While interpreting 
the scans, radiologists had unrestricted access to clinical information in the 
patients' electronic medical record, including results or films of prior radiographic 
studies. This includes access to prior PET or bone scans. For the purposes of this 
study, we considered tumor in a rib adjacent to the primary tumor as direct 
extension and not true distant metastasis. 
PET Imaging. Two hundred and fifty-six of the 257 patients underwent 
whole-body FDG-PET for staging of newly diagnosed lung cancer at DUMC. 
One patient received a PET study at an outside hospital and submitted the scans to 
DUMC for review. 
PET imaging was performed on aGE Advance unit 2-D acquisition mode. 
Prior to January 2000, non-attenuation-corrected scans were initially obtained for 
4 minutes per bed position from the level of the base of the brain through the 
middle of the thighs. A two bed position attenuation-corrected regional chest 
scan was then performed using 8 minutes for the emission scan and I 0 minutes 
for the transmission scan at each bed position. The images were reconstructed 
using a Haun filter with a cutoff of0.71/cm. 
PET studies performed after January 2000 used emission images obtained 
for 4 minutes per bed position from the level of the base of the brain through the 
middle of the thighs. Transmission images using a Germanium--68 rod source 
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were then obtained for 2.5 minutes per bed position. The images were 
reconstructed using OSEM (2 iterations) and segmented attenuation correction. 
Reconstructed images were 128 x 128 x 35 with 4.30 mm x 4.30 mm x 4.25mm 
voxels. The transaxial, coronal, sagittal, and maximum intensity projection (MIP) 
were reviewed on the vendor-supplied workstation. 
A single experienced nuclear medicine physician interpreted the PET 
study as positive for bone metastases if it contained a focal area of increased FDG 
uptake in bone greater than normal background bone activity. 38 The nuclear 
medicine physician interpreted the PET studies as negative if there was no 
significant FDG uptake. The study investigators retrospectively reviewed each 
PET report and coded it as 'positive', 'probable', 'unlikely', or 'negative' for the 
presence of distant bone metastasis. A thoracic radiologist with over a decade of 
experience with FDG-PET in lung cancer re-examined any reports of PET that 
described indeterminate or equivocal results along with the original study. He 
then coded these studies into one of the aforementioned diagnostic categories for 
bone metastasis. 
Bone Scintigraphy. Two hundred and thirty-four patients underwent 
radionuclide bone scintigraphy at DUMC. Twenty-three patients presented to 
DUMC with bone imaging performed at outside hospitals, the results of which we 
collected from clinic notes or reports by nuclear medicine physicians. 
Whole-body images were obtained in the anterior and posterior 
projections starting 2-3 hours following the intravenous injection of 430 f.l.Cilkg 




diphosphonate. Either a BodyScan (Nuclear Medicine Group, Siemens Medical 
Group, Hoffinan Estates, Til) or aT -22 Twin Detector Nuclear Imaging System 
(SMV, Twinsburg, Ohio) was used for the radionuclide bone imaging studies. 
Nuclear medicine physicians interpreted the bone scans according to 
standard clinical practice, using intensity, configuration, location, and number of 
foci of increased tracer activity. An experienced nuclear medicine physician 
interpreted the bone scintigraphy study as positive for bone metastasis if the 
radiotracer activity in the lesion was greater than normal bone. If there was no 
significant radio tracer uptake in the bones or radio tracer uptake was characteristic 
of benign disease, we coded the study as negative. If the location, distribution, 
and intensity of the radiotracer activity were indeterminate for differentiation 
between benign and metastatic disease, we coded the study as equivocal. We 
reviewed reports retrospectively and coded each as positive, probable, equivocal, 
unlikely, or negative for the presence of distant bone metastasis.33, 34 
Clinical-pathologic Correlation 
We analyzed all available clinical and pathologic information from patient 
records to determine the presence or absence of osseous metastatic disease at the 
time of initial staging. We entered all clinical data from clinic visits, radiographic 
studies, and followup into a database. 
Confirmation of Bone Metastases. We considered patients to have bone 
metastases if any of the following criteria were present: positive bone biopsy (n = 
6); progression of bony lesions seen on subsequent nuclear medicine studies 
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(PET, n = 1; bone scan, n = 12); radiographic confirmation by other imaging 
modalities (n = 18); or 0 3 osseous lesions on initial nuclear medicine studies 
(PET scan, n = 8; bone scan, n = 3). Additional criteria included concordant 
initial PET and bone scans with similar distribution of osseous lesions (n = 4); or 
in the setting of discordant initial PET and bone scans without follow-up, 
confirmation of metastatic disease at non-osseous distant sites by PET or biopsy 
constituted sufficient evidence to support the presence of bone metastasis (n = 5). 
Absence of Bone Metastases. We considered bone metastases to be 
absent if biopsy of a suspicious bone lesion was negative (n = 7) or suspicious 
bone lesions were not present on followup imaging studies within 1 month of 
initial staging (n = 112). In the absence of followup imaging studies, we 
considered patients with negative initial PET and bone scan and without clinical 
findings to have no bone metastasis (n = 81 ). 
Statistical Analysis 
We calculated sensitivity, specificity, positive predictive value, and 
negative predictive value along with 95% confidence intervals for PET and bone 
scintigraphy. We used the McNemar test was to compare the accuracy of PET 
and bone scintigraphy and calculated the weighted D(Pv) statistic to determine 
their agreement. The Q.., value is an adjustment of the percentage of agreement to 
accommodate for chance agreement. Clinicians have proposed the following 
values of Q.., to qualitatively evaluate agreement: poor (<0), slight (0-0.20), fair 




1.0).39 We performed all statistical analyses with the Stata version 7.0 (Stata 
Corporation, College Station, TX) software. 
RESULTS 
Patients 
Lung cancer histology and stage distribution are listed in Table 1. One 
hundred and four ( 40%) of the 257 patients presented with stage IV disease, and 
57 (22%) patients had osseous metastases by clinical-pathologic correlation. 
= 
For the calculation of sensitivity, specificity, and agreement, we combined ~ 
all 'positive' and 'probable' PET and bone scan results into one category of 
positive. Likewise, we combined all 'negative' and 'unlikely' PET and bone scan 
results into one category of negative. 
PET Scan 
PET scan was positive in 61 (24%) and negative in 196 (76%) patients. 
True positive PET. PET correctly identified bone metastases in 52 of the 
57 (91 %) patients with confirmed osseous disease. Bone scan found 21 patients 
with confirmed osseous Stage IV disease negative or equivocal for osseous 
metastasis, and PET correctly detected metastasis in 19 (90%) of these 21 
patients. Bone was the only site of metastatic disease in 2 (10%) of these 19 
cases. In 6 (32%) of the 19 patients, PET was the only initial staging study to 
identify distant metastasis and classify the patient as Stage IV. 
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False positive PET. In 9 patients, PET incorrectly identified 11 foci as 
positive for osseous metastasis. The lesions were noted in the spine (n = 5), ribs 
(n = 2), pelvis (n = 2), and acetabulum (n = 2). Bone scan accurately determined 
7 of these 9 patients to be negative for osseous metastases. In no case did the 
false positive PET result affect patient management or the decision to perform 
surgery. All patients proceeded to receive surgical resection or neoadjuvant 
chemotherapy. 
False negative PET. PET did not detect osseous metastases in 5 patients. 
Three of the 5 patients had a lesion outside of the region scanned by PET --{)ne in 
the calvarium, one in the lateral femoral condyle, and one in the distal fibula. 
Bone was the only site of distant metastasis in 2 ( 40%) of the 5 patients, but in 
both cases initial staging CT scans also provided evidence for Stage N disease. 
PET detected other non-osseous sites of distant metastasis in 2 ( 40%) of the 5 
patients. Therefore, futile surgical intervention was not performed on any patient 
with a false negative PET scan. L ~-
The sensitivity, specificity, and positive and negative predictive values of 
PET were 91% (95% CI, 81%- 97%), 96% (95% CI, 92%- 98%), 85% (95% CI, 
74%- 93%), and 97% (95% CI, 94%- 99%), respectively (Table 2). 
Bone Scan 
Bone scan was positive in 46 (18%), negative in 197 (77%), and equivocal 
in 14 ( 5%) patients. 
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True positive Bone Scan. Bone scintigraphy correctly identified 36 
(63%) of the 57 patients with bone metastases as positive. Of the 21 patients with 
osseous metastases not considered positive by bone scintigraphy, 7 had equivocal 
scans. Among the 57 patients with Stage N disease, PET missed metastatic 
lesions in 3 (5%) patients that bone scan found in the following locations: 
calvarium in 1 patient; mandible and fibula in 1 patient; and multiple lesions in 
the vertebral bodies, fibula, and femur in 1 patient. The lesion in the calvarium 
was outside the region scanned by PET, but routine staging head CT scan found 
it. Of the 3 patients, PET detected extraosseous, distant metastatic disease in 1 
patient. 
False positive Bone Scan. Bone scan incorrectly identified 15 benign 
foci as positive for metastatic disease in 10 patients. The locations of these foci 
were vertebral body (n = 3), skull (n = 3), rib (n = 3), sternum (n = 2), scapular tip 
(n = 1 ), costochondral junction (n = 1 ), mandible (n = 1 ), and vertebral pedicle (n 
= 1 ). PET correctly determined 9 of these 10 patients to be negative for osseous L 
metastases. In one unfortunate case, the false positive bone scan resulted in the 
patient being considered ineligible for curative surgical resection. 
False negative Bone Scan. Bone scan was negative in 14 patients with 
confirmed osseous metastases. Bone was the only site of distant metastasis in 2 
of the 14 patients. PET was positive in all 14 patients and was the only initial 
staging study to provide evidence of distant metastatic disease in 6 cases. 
Equivocal Bone Scan. Classification of all equivocal bone scan results as 
positive for metastatic disease yields the following values of sensitivity, 
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specificity, positive predictive value, and negative predictive value for bone 
scintigraphy: 75% (95% CI, 62%- 86%), 92% (95% CI, 87%- 95%), 72% (95% 
CI, 59%- 83%), and 93% (95% CI, 88%- 96%), respectively. Classification of 
equivocal bone scan results as negative yields corresponding values of 63% (95% 
CI, 49%- 76%), 95% (95% CI, 91%- 98%), 78% (95% CI, 64%- 89%), and 
90% (95% CI, 85%- 94%) (Table 3). 
Summary of PET aud Bone Scan Efficacy 
L 
A summary of sensitivity, specificity, positive and negative predictive F 
values of PET and bone scan is listed in Table 4. Application of PET and bone 
scan test characteristics to a hypothetical population of 1,000 patients is shown in 
Table 5. The rate of false-positive PET and bone scans is approximately 3-4%. 
False-negative PET scans account for 2% of results, whereas false-negative bone 
scans are a bit higher at 5.5%. Equivocal bone scans account for 5.5% ofresults. 
Likelihood Ratios 
Both PET and bone scan have likelihood ratios greater than 20 when 
'positive' (Table 6). Only PET has a likelihood ratio less than 0.10 when 
'negative' .40 In the category of 'probable', the likelihood ratios of PET and bone 
scan are 10.5 and 4.7, respectively. In the category of 'unlikely', the likelihood 
ratios of PET and bone scan are 0.27 and 0.80, respectively. Ninety-three percent 
of PET results are in the 'positive' or 'negative' diagnostic category, whereas 
74% of bone scan results are in the same categories. 
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Agreement and Accuracy 
Agreement between PET and bone scintigraphy findings was calculated as 
Q, = 0.510 (95% CI, 0.402- 0.618) (Table 7). 
Accuracy of PET (95%) is significantly greater than bone scintigraphy 
(90%) (p < 0.05) when equivocal bone scan results are excluded from the analysis 
(Table 8). McNemar's test is also significant when we consider all equivocal 
bone scintigraphy findings as either positive for metastatic disease (p < 0.05) or 
negative for metastatic disease (p < 0.001). 
DISCUSSION 
Once a new diagnosis of lung cancer has been established, an accurate 
assessment of the stage becomes crucial for providing prognosis information and 
deciding on treatment options. Physicians have traditionally determined clinical 
stage by a series of non-invasive radiologic and laboratory tests, which primarily 
demonstrate a gross anatomic distribution of disease. Conventional imaging 
studies are clearly less than optimal, as evidenced by the approximately 60% 5-
year survival rates of patients initially diagnosed with early stage lung cancer. 8 
These patients typically undergo curative resection, because there is no evidence 
for metastases, but ahnost 40% later recur with disease, which was not detected 
by conventional imaging modalities. 8 Thus the search continues for more 
accurate and efficient techniques to stratify patients for the most appropriate 
treatment protocols. 
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Over the last several years, FDG-PET has emerged as a novel and 
powerful imaging modality to complement CT scan for intrathoracic staging of 
lung cancer. 6 PET has also received attention for improved pre-operative, 
extrathoracic staging in candidates for surgical resection.23 Several studies have 
demonstrated improved detection over conventional imaging of otherwise 
unsuspected distant metastases with PET in all sites except for brain.14 
The results of this study are in keeping with those of previous studies, but 
these results must be viewed skeptically because of sub-optimal study design. 17" 
28, 30,31 This study suggests that PET scan is more sensitive and as specific as 
bone scan for the evaluation of distant osseous metastasis in patients with newly 
diagnosed lung cancer. Calculation of a single sensitivity value for bone scan is 
not possible because ofthe presence of equivocal results, but the true sensitivity 
lies somewhere between the worst-case and best-case sensitivity values of 63% 
(95% CI, 49%- 76%) and 75% (95% CI, 62%- 86%), respectively?3 Sensitivity 
of PET (91 %, 95% CI, 81%- 97%) is significantly greater than the worst-case 
estimate of bone scan sensitivity and trending toward statistical significance when 
compared to the best-case estimate. The agreement between PET and bone scan 
results with regard to distant osseous metastases is moderate. 
The likelihood ratios associated with PET scan and bone scan favor the 
use of PET scan. Test results provided by bone scan are not as definitive as PET, 
as evidenced by the higher percentage of test results in the intermediate diagnostic 
categories of 'probable', 'equivocal', and 'unlikely'. When 'positive', both PET 
and bone scan provide a large change in post-test probability with a likelihood 
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ratio greater than 20. But this value drops sharply to less than 5 for bone scan in 
the 'probable' diagnostic category. Likelihood ratios greater than 10 or less than 
0.1 are considered the most useful in changing post-test probability. Likelihood 
ratios of5-10 and 0.1-0.2 create moderate shifts in pre- to post-test probability. 
Likelihood ratios of0.2-5 are generally oflimited diagnostic utility.40 Bone scan 
had a likelihood ratio of 0.80 for 'unlikely' results, which comprised 15% of all 
bone scan results. 
The results of this study are subject to a variety ofbiases.34 The 
retrospective selection of patients can easily result in selection or spectrum bias.41 • 
42 Because DUMC is a major referral center, the expectation is that patients 
diagnosed with lung cancer by outside physicians will receive a PET scan at Duke 
only if no evidence of simultaneous metastatic disease is visualized by outside 
bone scan, thoracic CT, or brain CT scan. Such selection would reduce the 
prevalence of bone metastases in the study population and thus increase the 
difference in diagnostic efficiency of the two studies. An artificially low 
prevalence of metastatic disease in the study population spectrum would create a 
corresponding increase in the diagnostic efficiency of the two tests. The clinical 
reality may be that no statistically significant difference between the two tests 
exists among patients in the general population. However, the study population 
had a clinical stage distribution and prevalence of osseous metastases similar to 
lung cancer patients in the general population, of whom only 15% have localized 
disease and 20% osseous metastases at presentation.5• 43 Therefore, it is unclear 
whether selection bias played a large role in influencing the results of this study. 
25 
It is possible that patient selection somehow favored PET scan and 
underestimated the accuracy of bone scintigraphy by an unkown mechanism 
related to selection bias. 
Verification of the presence or absence of osseous metastasis at the time of 
initial staging with PET and bone scan is the most obvious source of bias. If this 
study has a fatal flaw, it is the lack of a rigorous and uniformly-applied diagnostic 
gold standard. While bone biopsy of the most suspicious lesions is the gold 
standard, physicians use it sparingly because of patient discomfort, and in many 
cases, results of the test would not change clinical management. Patients with 
initially positive PET or bone scan findings are more likely to receive subsequent 
investigation of bone lesions than those with negative scans, creating another 
form of verification bias known as work -up bias. 34 
Use of the results from initial PET and bone scans to verify metastatic 
disease creates incorporation bias. However, in this and all previous studies, the 
researchers employed the results of the PET and bone scans to varying degrees as 
evidence to determine the presence of metastasis or benign bone lesions. 
Incorporation bias refers to this use of circular logic. Other studies used a long 
follow-up period and the results of multiple bone scans or PET scans to minimize 
the incorporation bias of a single test result, preferring to rely on several results. 
Incorporation bias and verification bias are difficult problems to rectifY, 
since patients find the gold standard undesirable, and the existing diagnostic tests 
of PET and bone scan seem to have fairly good sensitivity and specificity. Given 





using a combination of long-term follow-up and other imaging modalities such as 
plain film and MR may be feasible. 
For patients diagnosed initially with no metastatic disease, it is difficult to 
prove the absence of such disease. Even the absence of bone lesions in follow-up 
radiographic studies does not conclusively prove the absence of osseous 
metastases at the time of initial staging, because these patients may simply be 
responding successfully to systemic chemotherapy or local radiation. 
Agreement between tbe results of PET scan and bone scintigraphy studies 
was moderate. This result is also subject to bias, namely test review bias.34 
Because unblinded radiologists reading the initial PET scan and bone scan may 
have used the result of the first study to interpret the second, tbe calculated Q, 
statistic may be artificially elevated. It is unclear how selection bias in this study 
affects the Q, statistic for agreement of PET and bone scan findings. 
Of note is tbe effect offalse-positive and false-negative results of PET 
scan and bone scan on patient management. False negative PET results had no 
adverse effect on patients, because all 5 (2%) patients had either simultaneous, 
non-osseous, extrathoracic metastases or the initial staging CT scans found the 
osseous metastases missed by PET. Similarly, false positive PET results did not 
result in any of the 7 (3%) patients being denied curative surgery. All patients 
proceeded to receive curative resection or neoadjuvant chemotherapy. However, 
in the case of false positive bone scans, I ofthe 10 (4%) patients was immediately 





(5%) patients with a false negative bone scan, PET scan was the only staging 
]____ 
study to provide evidence of Stage N disease. 
Cost-effectiveness analyses have demonstrated advantages to the addition 
of PET in the work-up of solitarypuhnonary nodules.44' 45 Lung cancer is the 
only neoplasm for which Medicare has approved reimbursement for FDG-PET in 
diagnosis, staging, and re-staging. If fused PET-CT does indeed become the gold 
standard of the future in lung cancer staging evaluations, then there is a potential 
cost savings of eliminating bone scan and relying completely on fused PET-CT 
scans. However, to date there is no conclusive evidence that PET can replace 
bone scintigraphy. A future study ofbetter quality may eventually change the 
role ofbone scan to that of a second-line, alternative imaging modality used only 
in cases of diagnostic uncertainty. Further research of this area should be 
performed in a well-designed, prospective, clinical trial to minimize bias. 
A randomized, controlled trial can be used to evaluate the effect of PET 
scan and bone scan in the management of bone metastases and overall mortality 
oflung cancer patients. The three arms of the trial would be PET scan only, bone 
scan only, and both PET and bone scan for the detection of osseous metastasis. In 
an alternative, non-randomized trial design, investigators can perform both PET 
scan and bone scan on all patients. Investigators would selectively blind 
clinicians to the results of one or the other test and ask the clinicians to record 
their clinical management plans. Then, the clinician would record clinical 
management plans based on the information from both tests. 46 Investigators 
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would determine which strategy resulted in the highest sensitivity and specificity. 
This type of design can be used in a cost-effective analysis. 
Blinding is imperative in studies of diagnostic efficiency. 36• 37 For this 
particular clinical question of assessing bone metastasis in lung cancer patients, 
the most important aspect of the study design is an a priori protocol for the work-
up and verification of suspicious osseous foci as benign or metastatic. When bone 
biopsy is not performed, rigorous diagnostic criteria should be employed as a 
L 
substitute gold standard. The substitute gold standard will most likely require the 
judicious use of other imaging modalities and an extended follow-up period of 
approximately one year or more. Special attention is required to determine the 
optimal period of follow-up with PET scan and bone scan, the effect oflocalized 
radiation therapy or systemic chemotherapy on the subsequent detection of 
osseous metastases, and the clinical significance of equivocal bone scan results. 
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TABLEt 
Histological Diagnosis and Stage Distribution of Study Population 
Histology 
Non-small cell lung cancer, otherwise unspecified 
Adenocarcinoma 
Squamous cell carcinoma 
Small cell lung carcinoma 
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TABLE2 
PET versus Clinical Pathologic Findings of Bone Metastasis 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence of bone metastases 
Sensitivity 
52/57= 91% (95% CI, 81%- 97%) 
Specificity 
191/200 = 96% (95% CI, 92% - 98%) 
PET Findings 
Positive Negative 
Positive Predictive Value 
52/61 = 85% (95% CI, 74%- 93%) 
Negative Predictive Value 
191/196 = 97% (95% CI, 94%- 99%) 
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TABLE3 
Radionuclide Bone Scintigraphy versus Clinical Pathologic Findings 
Clinical Pathologic Findings 
Confmned bone metastases 
Absence of bone metastases 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence of bone metastases 
Bone Scintigraphy Findings 
Positive Negative Equivocal 
Bone Scintigraphy Findings 
Positive Negative 
*equivocal bone findings are considered positive for metastatic disease 
Sensitivity 
43/57 = 75% (95% CI, 62%- 86%) 
Specificity 
183/200 = 92% (95% CI, 87%- 95%) 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence of bone metastases 
Positive Predictive Value 
43/60 = 72% (95% CI, 59%- 83%) 
Negative Predictive Value 
183/197 = 93% (95% CI, 88%- 96%) 
Bone Scintigraphy Findings 
Positive Negative 
*equivocal bone findings are considered negative for metastatic disease 
Sensitivity Positive Predictive Value 
36/57 = 63% (95% CI, 49%- 76%) 36/46 = 78% (95% CI, 64%- 89%) 
Specificity Negative Predictive Value 







Comparison of PET and Bone scan Test Characteristics 
PET Bone scan Bone scan 
( equivocal->positive) ( equivocal->negative) 
Seositivity 0.91 (0.81,0.97) 0.75 (0.62,0.86) 0.63 (0.49,0.76) 
Specificity 0.96 (0.92,0.98) 0.92 (0.87,0.95) 0.95 (0.91,0.98) 
Positive predictive value 0.85 (0.74,0.93) 0.72 (0.59,0.83) 0.78 (0.64,0.89) 
Negative predictive value 0.97 (0.94,0.99) 0.93 (0.88,0.96) 0.90 (0.85,0.94) 
95% confidence mtervals hsted m parantheses 
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TABLES 
Results of PET and Bone scan in Hypothetical Population (n = 1 000) 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence ofbone metastases 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence ofbone metastases 
PET Findings 
Positive Negative 
Bone Scintigraphy Findings 
Positive Negative Equivocal 
1140 155 127 





Comparison of PET and Bone scan Likelihood Ratios 
Clinical Pathologic Findings 
Confirmed bone metastases 
Absence of bone metastases 
LR,witive = 21.5 
LR,rob>blo = I 0.5 
LRmliiko!y = 0.27 
LRnegative = 0.08 
Clinical Pathologic Findings 
Confrnned bone metastases 
Absence ofbone metastases 
LR,,,itive = 24.6 
LRprob,blo = 4.7 
LRequivocal = 3 .5 
LRmliikoiy = 0.80 
LRnegative = 0.16 
PET Findings 
Positive Probable Unlikely Negative 
49 3 1 4 
8 1 13 178 
22% 2% 5% 71% 
Bone Scintigraphy Findings 
Positive Probable Equivocal Unlikely 
28 8 7 7 
4 6 7 31 








Agreement Between PET and Radionuclide Bone Scintigraphy Findings 





















Bone Scintigraphy Findings 
Correct Incorrect E uivocal 
209 23 
10 1 
McNemar's test (ignoring equivocal results) 
McNemar Chi Square p = 0.035 
Bone Scintigraphy Findings 
PET Findings Correct Incorrect 
Correct I ~~4 I ;9 
Incorrect . 
*equivocal bone fmdings are considered positive for metastatic disease 
McNemar's test (counting all equivocal results as positive for metastatic disease) 
McNemar Chi Square p = 0.012 
Bone Scintigraphy Findings 
PET Findings Correct Incorrect 
Correct 
Incorrect 
*equivocal bone fmdings are considered negative for metastatic disease 
McNemar's test (counting all equivocal results as negative for metastatic disease) 
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